

Grisnilimab Biosimilar - Research Grade

Product Code: ICH5584-10mg

More Information

Species Reactivity: Human

Target: CD7

Concentration: >1mg/ml

Isotype: IgG2a - lambda

Host: CHO Cells

product name H2: Grisnilimab Biosimilar - Research Grade

Antibodies against the same target: [Bulk Anti-Human CD7 \(T3-3A1\) Antibody \(ICH1158\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of grisnilimab, an anti-CD7 monoclonal antibody, supplied for research use only. It reproduces the antigen-binding specificity of the originator against human CD7 while being manufactured as a research-grade reagent rather than a clinical drug; it is not intended for human or veterinary use. The molecule is a full-length recombinant IgG2a-lambda immunoglobulin, useful because it gives researchers a defined, reproducible binder against CD7 for characterizing target expression, epitope engagement, and downstream signaling. Typical research contexts include isotype-matched and target-specific controls, comparability and bridging studies, in-vitro binding and neutralization assays, flow cytometry and immunoassay development, and preclinical model work where a consistent anti-CD7 reagent is needed. It is offered at low endotoxin levels (research grade under 1 EU/mg; ultra-low under 0.5 EU/mg) and in bulk milligram-to-gram quantities to support in-vitro and in-vivo standard workflows, biosimilar comparability programs, and larger

screening campaigns requiring lot-to-lot consistency. CD7 is a 40 kDa transmembrane glycoprotein of the immunoglobulin superfamily, expressed on the majority of thymocytes and mature T lymphocytes, on natural killer cells, and on early myeloid and lymphoid progenitors; it appears among the earliest antigens during T-cell ontogeny. Its cytoplasmic tail links to PI3-kinase signaling, and cross-linking of surface CD7 acts as a costimulatory signal that can enhance T-cell and NK-cell activation, calcium flux, adhesion-molecule expression, and cytokine secretion. CD7 is widely retained on T-cell and NK-cell malignancies, including T-cell acute lymphoblastic leukemia and certain acute myeloid leukemias, which makes it a prominent target of interest for immunophenotyping and for antibody-directed and cell-therapy approaches against these cancers.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks

Suggested H1: Grisolimab (anti-CD7) Biosimilar

FAQ (Q&A):

Q: Is the Grisolimab biosimilar available in bulk or gram quantities?

A: Yes — the Grisolimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Grisnilimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Grisnilimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Grisnilimab that binds CD7.